Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence

This study is currently recruiting participants.

Verified by Hadassah Medical Organization, November 2005

First Received: December 4, 2005 Last Updated: March 19, 2007 History of Changes

Sponsors and Collaborators:	Hadassah Medical Organization Beth Israel Deaconess Medical Center
Information provided by:	Hadassah Medical Organization
ClinicalTrials.gov Identifier:	NCT00262093

Purpose

The reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients.

Condition
Pre-Eclampsia

Study Type:	Observational
Study Design:	Screening, Cross-Sectional, Case Control, Prospective Study
Official Title:	Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence

Further study details as provided by Hadassah Medical Organization:

Estimated Enrollment:	200
Study Start Date:	November 2005

Detailed Description:

Primiparity is one of the main risk factors for having preeclampsia during pregnancy. Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia.

Higher sFlt-1 mRNA, higher serum levels of sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic patients. We intend to check the angiogenesis profile of primiparas as compared to multiparas.

Eligibility

Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Every delivery

Exclusion Criteria:

Preeclampsia or pregnancy induced hypertension

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00262093

Contacts

Contact: Yuval Bdolah, MD, MSc	972-2-5844111	ybdolah@hadassah.org.il
Contact: Hadas Lemberg, PhD	972-2-6777572	lhadas@hadassah.org.il

Locations

Israel
Hadassah Medical Organization	Recruiting
Jerusalem, Israel, 91240
Contact: Arik Tzukert, DMD 972 2 6776095 arik@hadassah.org.il
Contact: Hadas Lemberg, PhD 972 2 6777572 lhadas@hadassah.org.il
Principal Investigator: Yuval Bdolah, MD

Sponsors and Collaborators

Hadassah Medical Organization

Beth Israel Deaconess Medical Center

Investigators

Principal Investigator:

Yuval Bdolah, MD, MSc

Hadassah-Hebrew University Medical School

More Information

No publications provided

Study ID Numbers:	PRIMIMULTI-HMO-CTIL
Study First Received:	December 4, 2005
Last Updated:	March 19, 2007
ClinicalTrials.gov Identifier:	NCT00262093 History of Changes
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:

preeclampsia
sFlt1
PlGF
parity
angiogenesis

Study placed in the following topic categories:

Hypertension, Pregnancy-Induced
Pregnancy Complications
Eclampsia

Pre-Eclampsia
Preeclampsia
Hypertension

Additional relevant MeSH terms:

Hypertension, Pregnancy-Induced
Pregnancy Complications
Eclampsia
Pre-Eclampsia

ClinicalTrials.gov processed this record on August 30, 2009